| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 45,328 | 49,379 | 36,429 | 61,122 |
| Depreciation and amortization | 1,839 | 2,046 | 2,023 | 4,027 |
| Loss on extinguishment of debt | NaN | 0 | -2,177 | -1,159 |
| Gain on sale of plasma centers | 7,980 | NaN | NaN | NaN |
| Loss on disposal of fixed assets | -42 | -9 | 0 | 0 |
| Deferred income tax provision | NaN | -11,020 | NaN | NaN |
| Interest paid in kind | NaN | 0 | NaN | NaN |
| Deferred income tax provision | -6,556 | NaN | 4,803 | 5,045 |
| Stock-based compensation | 6,329 | 5,392 | 5,047 | 9,587 |
| Amortization of debt discount | 191 | 197 | 170 | 350 |
| Amortization of license revenue | -36 | -36 | -36 | -71 |
| Accounts receivable | -22,567 | 20,756 | 27,948 | 59,726 |
| Inventories | 15,633 | 9,798 | 5,203 | 21,229 |
| Prepaid expenses and other current assets | 1,601 | 547 | -1,117 | 2,095 |
| Deposits and other assets | -379 | -540 | -45 | 306 |
| Accounts payable | -1,233 | -2,203 | -4,876 | 9,409 |
| Accrued expenses | 5,105 | 10,639 | -221 | -5,206 |
| Other current and non-current liabilities | -340 | -395 | -234 | -602 |
| Net cash provided by (used in) operating activities | 58,249 | 35,639 | 13,293 | 1,464 |
| Purchase of property and equipment | 2,543 | 1,084 | 14,368 | 7,123 |
| Acquisition of intangible assets | 53 | 192 | 0 | 124 |
| Deposit received on net assets held for sale | NaN | 1,000 | NaN | NaN |
| Proceeds on the sales of assets held for sale | 5,000 | NaN | NaN | NaN |
| Net cash provided by (used in) investing activities | 2,404 | -276 | -14,368 | -7,247 |
| Term loan payments-Ares Credit Facility | NaN | 0 | 32,500 | NaN |
| Ares revolving facility payments-Ares Credit Facility | NaN | 0 | 72,500 | NaN |
| Ares revolving facility proceeds-Ares Credit Facility | NaN | 0 | 30,000 | NaN |
| Jpm term loan payments | 469 | 469 | 469 | NaN |
| Payment of end of term fee | NaN | 1,313 | 1,313 | 375 |
| Jpm revolving facility proceeds | 125,000 | 0 | 75,000 | NaN |
| Prepayment penalties on repayment of debt | NaN | 0 | 581 | 450 |
| Proceeds from issuance on revolver | NaN | NaN | NaN | 30,000 |
| Proceeds from issuance of note payable | NaN | 0 | NaN | NaN |
| Taxes paid on vested restricted stock units | 5,058 | 164 | 964 | 8,419 |
| Payments on finance lease obligations | NaN | 0 | NaN | NaN |
| Principal payments on term loan | NaN | NaN | NaN | 30,000 |
| Debt issuance costs | NaN | 13 | 2,224 | NaN |
| Payment of deferred financing fees | NaN | 0 | NaN | NaN |
| Net proceeds from the exercise of stock options | 588 | 430 | 389 | 2,165 |
| Acquisition of treasury stock | 130,191 | 8,902 | 23,038 | NaN |
| Net cash used in financing activities | -10,130 | -9,118 | -27,825 | -7,079 |
| Net increase (decrease) in cash and cash equivalents | 50,523 | 26,245 | -28,900 | -12,862 |
| Cash and cash equivalents - beginning of period | 87,630 | 61,385 | 375 | NaN |
| Cash and cash equivalents - end of period | 138,153 | 87,630 | 61,385 | NaN |
ADMA BIOLOGICS, INC. (ADMA)
ADMA BIOLOGICS, INC. (ADMA)